Global Vascular Grafts and Peripheral Stents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

혈관 이식편 및 주변 스텐트 시장 분석

혈관 이식편 및 말초 스텐트 시장은 심혈관 질환의 유병률 증가, 최소 침습 기술의 발전, 고령 인구 증가에 힘입어 강력한 성장을 경험하고 있습니다. 합성 및 생합성 재료가 주도하는 이 시장은 향상된 생체 적합성과 내구성의 혜택을 받고 있습니다. 최근 개발된 제품으로는 재협착 위험을 크게 줄이고 환자 결과를 개선하는 혁신적인 약물 용출 스텐트가 있습니다. 또한 생분해성 스텐트의 등장으로 장기적인 합병증이 줄어들어 의료 서비스 제공자의 관심을 끌고 있습니다. 기업들이 차세대 제품을 개발하기 위해 R&D에 투자함에 따라 시장은 의료 지출 증가와 전 세계 의료 서비스 접근성 개선에 힘입어 지속적인 확장을 앞두고 있으며, 이는 미래 혁신과 치료에 대한 긍정적인 전망을 반영합니다.

혈관 이식편 및 주변 스텐트 시장 규모

글로벌 혈관 이식편 및 주변 스텐트 시장 규모는 2023년에 37억 2천만 달러로 평가되었으며, 2031년까지 59억 3천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.00%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

혈관 이식편 및 주변 스텐트 시장 동향

“ 약물 방출 기술의 채택 증가”

혈관 이식편 및 말초 스텐트 시장은 혈관 질환이 있는 환자의 치료에 혁명을 일으키고 있는 약물 용출 기술의 채택이 증가하고 있는 것입니다. 이러한 기술은 시술 후 재협착 또는 혈관의 재협착을 예방하는 데 도움이 되는 약물로 스텐트를 코팅하는 것을 포함합니다. 약물 용출 스텐트는 영향을 받는 부위에 직접 약물을 전달하여 동맥 막힘 위험 과 반복적인 개입의 필요성을 줄여 환자 결과를 크게 개선합니다. 말초 동맥 질환(PAD)에 대한 인식이 계속 증가함에 따라 의료 서비스 제공자는 이러한 고급 스텐트를 점점 더 선택하고 있으며, 더 효과적이고 오래 지속되는 결과를 제공할 수 있는 잠재력을 인식하고 있습니다. 또한 최소 침습적 시술에 대한 광범위한 추세는 약물 용출 스텐트에 대한 수요를 촉진하고 있습니다. 이러한 장치는 더 빠른 회복 시간, 낮은 합병증 발생률 및 전반적인 환자 경험을 제공하기 때문입니다. 결과적으로 약물 전달 시스템을 혈관 개입에 통합함으로써 혁신이 촉진되고 시장 환경이 변화하고 있습니다.

보고 범위 및 혈관 이식 및 주변 스텐트 시장 세분화

혈관 이식편 및 주변 스텐트 시장 정의

혈관 이식편과 말초 스텐트는 다양한 혈관 질환을 치료하는 데 사용되는 필수적인 의료 기기입니다. 혈관 이식편은 손상된 혈관 을 대체하거나 우회하여 혈관 질환이나 동맥류가 있는 환자의 혈류를 개선합니다. 이러한 이식편은 합성, 생합성 또는 생물학적 재료로 제작할 수 있어 특정 의료적 요구에 맞는 옵션을 제공합니다. 반면 말초 스텐트는 좁아지거나 막힌 동맥, 특히 사지에 삽입하여 혈관 개통을 유지하고 혈액 순환을 회복하는 메시 모양의 튜브입니다. 두 기기 모두 더 나은 혈류를 촉진하고 혈관 질환과 관련된 합병증 위험을 줄임으로써 환자 결과를 크게 개선합니다.

혈관 이식편 및 주변 스텐트 시장 동향

운전자

• 심혈관 질환의 증가 발생률

관상동맥질환, 말초동맥질환, 동맥류와 같은 질환의 발병률이 증가하는 것은 혈관 이식편과 스텐트에 대한 수요를 견인하는 주요 요인입니다. 세계보건기구에 따르면, 심혈관 질환은 전 세계적으로 사망의 주요 원인으로, 매년 약 1,790만 명이 사망하는 것으로 추산되며, 이는 효과적인 치료 옵션에 대한 시급한 필요성을 강조합니다. 이러한 질환이 앉아서 생활하는 방식, 비만, 인구 고령화와 같은 요인으로 인해 더 널리 퍼지면서, 의료 서비스 제공자는 이러한 질환을 관리하고 치료하기 위해 혈관 개입에 점점 더 의존하고 있습니다. 이러한 증가하는 환자 인구는 혈류를 회복하고 심각한 합병증을 예방하기 위해 혈관 이식편과 스텐트를 사용해야 하며, 이를 통해 심혈관 건강 관리의 이 중요한 부문에서 혁신과 투자를 촉진합니다.

• 최소 침습 수술 기술

The shift towards minimally invasive surgical techniques has revolutionized the approach to treating vascular conditions, significantly improving patient outcomes. These techniques, which include procedures like endovascular stent placement and laparoscopic grafting, allow for smaller incisions and less trauma to the body. As a result, patients experience shorter recovery times, reduced pain, and fewer complications compared to traditional open surgeries. This efficiency encourages healthcare providers to adopt these methods more frequently, leading to an increase in the utilization of vascular grafts and stents. In addition, the enhanced precision of minimally invasive procedures can lead to better long-term results, further driving demand for these advanced medical devices. Overall, this trend benefits patients and contributes to a more efficient healthcare system.

Opportunities

• Enhancing Treatment Efficacy and Safety

Innovations in the vascular grafts and peripheral stents market present significant growth opportunities by enhancing treatment efficacy and safety. Bioresorbable stents, which gradually dissolve in the body, reduce long-term complications associated with permanent implants, making them appealing for both patients and healthcare providers. Drug-eluting stents, designed to release medication that prevents restenosis, further improve patient outcomes by minimizing the risk of artery narrowing after procedures. In addition, advancements in graft materials, particularly biocompatible polymers, enhance biocompatibility and reduce adverse reactions. These innovations not only revolutionize treatment protocols but also create a competitive edge for manufacturers, opening new revenue streams and increasing market demand as healthcare providers seek safer, more effective solutions for vascular diseases.

•  Improvement of Healthcare Infrastructure in Developing Regions

The improvement of healthcare infrastructure in developing regions presents a significant market opportunity for companies in the vascular grafts and peripheral stents sector. As these areas enhance their medical facilities and expand healthcare services, access to vascular treatments is increasing. This trend is crucial given the rising prevalence of vascular diseases such as peripheral artery disease and coronary artery disease in these populations. Companies can capitalize on this opportunity by introducing innovative, affordable products tailored to local needs, collaborating with healthcare providers, and engaging in public health initiatives. By addressing the unique challenges and demands of these markets, businesses can not only boost their sales but also play a vital role in improving health outcomes, creating opportunities for long-term growth and sustainability.

Restraints/Challenges

• High Costs of Development

The significant investment required for research, development, and clinical trials represents a considerable barrier in the vascular grafts and peripheral stents market, especially for smaller companies. These organizations often face financial constraints that limit their ability to undertake the extensive resources needed for innovative product development. The process of conducting clinical trials is not only lengthy but also costly, requiring substantial funding for materials, personnel, and compliance with regulatory standards. In addition, the risk of failure during trials can deter potential investors, further restricting funding opportunities. As a result, smaller companies may find it challenging to compete with larger players, leading to slower innovation and reduced diversity in product offerings within the market.

• Complex Regulatory Requirements

The lengthy and complex regulatory approval processes are a significant restraint in the vascular grafts and peripheral stents market, often delaying the introduction of new products and limiting market entry for innovative solutions. Companies must navigate intricate frameworks set by regulatory bodies, which require extensive documentation, clinical trial data, and compliance with stringent safety and efficacy standards. This protracted process can extend over several years, allowing competitors to launch similar products and saturate the market, thereby diminishing the potential impact of new innovations. In addition, the uncertainty surrounding approval timelines can deter investment, particularly for smaller firms that may lack the financial resources to endure prolonged development phases. As a result, these regulatory hurdles stifle innovation and restrict the availability of advanced solutions for patients and healthcare providers.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Vascular Grafts and Peripheral Stents Market Scope

The market is segmented on the basis of product type, vascular graft raw material source, vascular graft indication, peripheral stent artery type, vascular graft application, and end users.The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Vascular Graft
  • Endovascular Stent Graft
  • Peripheral Vascular Graft
  • Hemodialysis Access Graft
  • Bypass Graft
• Others
  • Peripheral Stent

Vascular Graft Raw Material Source

• Synthetic
  • Polytetrafluethylene (PTFE)
  • Polyurethane (PU)
  • Dacron
  • Others
• Biological
  • Bovine Vein
  • Saphenous Vein
  • Others
• Biosynthetic
  • Ovine Collagen with Polyester
  • Others

Vascular Graft Indication

• Endovascular Aneurysm Repair
• Peripheral Vascular Repair
• Hemodialysis Access

Peripheral Stent Artery Type

• Carotid Artery
• Fem-Pop Artery
• Iliac Artery
• Infrapop Artery

Vascular Graft Application

• Coronary Artery Disease
• Vascular Occlusion
• Aneurysm
• Renal Failure
• Others

End Users

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories
• Specialty Clinics
• Others

Vascular Grafts and Peripheral Stents Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, raw material source, indication, artery type, application, and end users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global vascular grafts and peripheral stents market in both market share and revenue, and this trend is expected to continue from 2024 to 2031. The region benefits from significant investments in research and development, bolstered by government initiatives aimed at enhancing healthcare. In addition, improvements in healthcare infrastructure across various countries further support the region’s dominant position in the market.

Asia-Pacific region is anticipated to record the highest growth rate in the global vascular grafts and peripheral stents market from 2024 to 2031 This growth is driven by rising government investments in the healthcare sector, aimed at improving access and quality of care. In addition, ongoing technological advancements and supportive government initiatives are further propelling the region’s market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Vascular Grafts and Peripheral Stents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Vascular Grafts and Peripheral Stents Market Leaders Operating in the Market Are:

• GSK plc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• AstraZeneca (U.S.)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (U.S.)
• Amgen Inc. (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED. (Japan)
• AB Science (France)
• Eisai Co., Ltd. (Japan)
• Genentech, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)

Latest Developments in Vascular Grafts and Peripheral Stents Market

• In September 2023 Recently, the Castor Branched Aortic Stent-Graft and Delivery System (Castor Branched Stent-Graft), the Minos Abdominal Aortic Stent-Graft and Delivery System (Minos Stent-Graft), and the Hercules Thoracic Stent Graft System with Low Profile Delivery System (Hercules LP Stent Graft) have received registration approval from the Thailand Food and Drug Administration (TFDA). These three products represent Endovastec's key offerings for endovascular interventions targeting thoracic and abdominal aortic diseases
• In Aug 2022 W. L. Gore & Associates, Inc. (Gore), a global leader in material science committed to transforming industries and enhancing lives, has announced the acquisition of InnAVasc Medical, Inc., a privately-held medical technology firm dedicated to improving care for patients with end-stage renal disease who rely on graft circuits for dialysis treatment

SKU-36483